When the A1C level is 9% or more, the American Diabetes Association suggests the use of long-acting (basal) insulin to augment therapy in patients taking one or two oral agents, or one oral agent, plus a glucagon-like peptide 1 receptor agonist. This is especially true if the patient has symptoms of hyperglycemia or catabolism.
Benefits of insulin therapy:
Concerns about insulin therapy:
Insulin analogs have a lower risk of hypoglycemia than human insulin, but at a higher cost – Please click here for more information.
An overview of Lantus, Toujeo, Basaglar and Tresiba is found on page 35 of the above referenced article. Please note: the article mentions Ryzodeg, which has not been launched in the United States.